Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Business

Biotech, pharma, and money in science

Biotech

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

By Adam Feuerstein

Pharma

U.S. panel considers giving a nod to new vaccine, and a competitor objects

By Helen Branswell

advertisement

Biotech

This investor predicted the big biotech stock rally. And he thinks it has legs

By Adam Feuerstein

advertisement

Business

Could a vaccine deter opioid addiction? U.S. taxpayers are subsidizing research

By Rebecca Robbins

Biotech

Will Trump’s FDA relax standards for drug approval? We’ll get a clue soon with decision on Portola’s anticoagulant

By Adam Feuerstein

Pharma

Turning to the states to solve the national problem of drug pricing

By Meghana Keshavan

Biotech

Meet the scientist who keeps J&J up with the Joneses

By Damian Garde

advertisement

Business

Families sue health insurers to cover wilderness therapy for mental illness

By Liz Kowalczyk — Boston Globe

advertisement

Pharma

With Cambridge life-sciences center, Bayer raises its profile

By Robert Weisman

Biotech

Camille Samuels: Favoring ‘new markets for unmet needs’

By Meghana Keshavan

Politics

Despite pressure over prices, the drug industry is coasting on Capitol Hill

By Erin Mershon

Biotech

Biotech R&D costs are outpacing revenues, but funding is still strong, report says

By Meghana Keshavan

Politics

As biotech elite gather, foreign countries aim to woo them with wine, cheese — and promises of a friendly political climate

By Rebecca Robbins

In the Lab

Are drug makers overlooking the next big category of sleep drugs?

By Rebecca Robbins

Biotech

How John Flannery recast GE Healthcare and its biologics business

By Karen Weintraub

Business

Sculley on digital health care: ‘the most interesting thing I’ve seen since Apple’

By Robert Weisman

Biotech

Personalized cancer therapies show great promise. The hitch? Manufacturing them efficiently

By Meghana Keshavan

Business

Saying Los Angeles lacks a great cancer center, Soon-Shiong plans to open one

By Rebecca Robbins

Politics

NIH drops controversial plan to cap funding for individual labs

By Robert Weisman

Biotech

Vertex goes all-in on its effort to conquer cystic fibrosis

By Robert Weisman

Business

Signs of the booming business of sleep: gadgets, didgeridoos, and free coffee

By Rebecca Robbins

Business

This insulin maker is running out of money. Its solution? Reality TV

By Rebecca Robbins

Don't Miss

The Real World, Diabetes: As cameras roll at a Jamaican resort, desperate patients seek healing

By Rebecca Robbins

Biotech

Three key stories we’re watching for at ASCO

By Damian Garde

Business

Resurrected: A controversial trial to bring the dead back to life plans a restart

By Kate Sheridan

In the Know

Dan Budwick: Telling biopharma’s story in plain English (even when that sparks a fight)

By Ike Swetlitz

Business

CRISPR stocks sank on news the gene editing tool can veer off target. But that’s hardly news

By Sharon Begley

Business

How a Supreme Court ruling on printer cartridges could have a big impact on drug prices

By Meghana Keshavan

Pharma

Medicare patients don’t share in drug discounts given insurers and PBMs

By Sarah Jane Tribble — Kaiser Health News

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT